Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Open-Label Study of ZACTIMA (vandetanib) 100 mg Monotherapy in Hereditary Medullary Thyroid Cancer
2006-001354-28Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vandetanib in Medullary Thyroid Cancer (MTC), sponsored by AstraZeneca. Primary endpoint: Objective response rate. Started Apr 2006; status: completed.
02
Drugs
vandetanib
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on 2006-001354-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001354-28.